Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Organon (OGN) to $9 from $10 and keeps an Equal Weight rating on the shares. The company, which announced that it had identified and ceased the improper sales practices that resulted in recent personnel changes and concluded that improper practices were limited to Nexplanon, lowered revenue guidance to $6.2B-$6.25B from $6.275B-$6.375B, predominantly driven by U.S. policy headwinds for Nexplanon and challenges in the respiratory business, the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN:
- Organon & Co. Reports Modest Q3 Revenue Growth
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Morning Movers: Monday.com sinks following third quarter results
- Organon cuts FY25 revenue view to $6.2B-$6.25B from $6.28B-$6.38B
- Organon reports Q3 adjusted EPS $1.01, consensus 93c